Nkarta reports FY2025 net loss of $104.1M; cash runway into 2029

Nkarta, Inc.

Cash, equivalents and investments $295.1M at Dec 31, 2025; expected to fund operations into 2029.
Full-year net loss $104.1M ($1.41 per share); Q4 net loss $27.4M ($0.37 per share).
NKX019 dose escalation advanced to 4 billion cells per dose in Ntrust-1 and Ntrust-2 trials.
Initial clinical data from Ntrust-1 and Ntrust-2 planned for presentation at a medical conference in 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Nkarta, Inc. reported the fourth quarter and year ended December 31, 2025 results: net income Net loss was $104.1 million, or $1.41 per basic and diluted share, for the full year 2025. Net loss was $27.4 million, o, EPS $1.41 per basic and diluted share (full year); $0.37 per basic and diluted share (fourth quarter).

Period: the fourth quarter and year ended December 31, 2025
Net income: Net loss was $104.1 million, or $1.41 per basic and diluted share, for the full year 2025. Net loss was $27.4 million, o
EPS: $1.41 per basic and diluted share (full year); $0.37 per basic and diluted share (fourth quarter)
Result: reported results

Exact text from the filing

On March 25, 2026, Nkarta, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0001787400-26-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.